a valued OOSS Marketing Partner:
Mobius Therapeutics, LLC, is a commercial stage venture focused on ophthalmic surgery solutions. Mitosol®, its first product, has been recognized by the Ophthalmic Mutual Insurance Company as "the FDA approved ophthalmic formulation of Mitomycin-C." The Mitosol®, (mitomycin for solution) 0.2 mg/vial Kit for Ophthalmic is reconstituted on the sterile field before use to reduce risk of drug degradation. Its closed delivery system protects operating personnel by containing hazardous mitomycin vapors. To learn more, click here.